Ohyama K, Uchide N, Suzuki R, Iwamoto N, Bessho T, Watanabe H, Hirakawa S, Yamakawa T
Department of Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Hachioji, Japan.
Cancer Detect Prev. 2000;24(1):61-71.
We investigated biosynthesis of Vicia graminea lectin (VGA)- and Vicia unijuga lectin (VUA)-binding (Vgu) glycoproteins, which are human malignant tumor-associated antigens, in cultured human tumor and non-tumor cells by pulse-labeling experiments with [35S]-methionine, followed by immunoprecipitation using immobilized VUA, SDS-PAGE and autofluorography. It was shown that Vgu glycoproteins synthesized by tumor cells were 15-30 times greater than those of non-tumor cells. It was also shown that about 40-70% of Vgu glycoproteins synthesized by non-tumor cells were secreted from the cells while more than 80% of the antigen synthesized by tumor cells was not secreted, and that Vgu glycoproteins consisted of multiple molecular species with the same epitope. To estimate the epitope structure of Vgu glycoproteins, in preliminary experiments we prepared sialoglycoproteins and/or sialoglycopeptides from purified human glycophorin A. Human glycophorins A(M) and A(N) (GPs-A(M) and A(N)) were treated with Clostridium perfringens neuraminidase to remove all sialic acid residues linked to carbohydrate chains, with Newcastle disease virus (NDV) to remove alpha2-3 linked sialic acid residues, and by Edman's degradation to eliminate N-terminal amino acid of GP-As. Partial or complete desialylation reactions resulted in disappearance of the reactivity of GP-A(M) and GP-A(N) with corresponding antisera and in appearance of reactivities with VUA and VGA. Elimination of N-terminal amino acid of GP-As also resulted in appearance of reactivities with VUA. These results show that sialoglycoproteins with similar serological properties of Vgu glycoprotein could be prepared from GP-As, and suggest that the epitope structure of Vgu glycoprotein may be related to the MN blood type-epitope structure and its sialic acid residues at N-terminal moiety of GP-As.
我们通过用[35S] - 甲硫氨酸进行脉冲标记实验,随后使用固定化的野豌豆单叶凝集素(VUA)进行免疫沉淀、十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳(SDS - PAGE)和放射自显影,研究了在培养的人肿瘤细胞和非肿瘤细胞中,作为人类恶性肿瘤相关抗原的与野豌豆草凝集素(VGA)和野豌豆单叶凝集素(VUA)结合的(Vgu)糖蛋白的生物合成。结果表明,肿瘤细胞合成的Vgu糖蛋白比非肿瘤细胞合成的多15 - 30倍。还表明,非肿瘤细胞合成的Vgu糖蛋白约40 - 70%分泌到细胞外,而肿瘤细胞合成的抗原超过80%未分泌,并且Vgu糖蛋白由具有相同表位的多种分子形式组成。为了估计Vgu糖蛋白的表位结构,在初步实验中,我们从纯化的人血型糖蛋白A制备了唾液酸糖蛋白和/或唾液酸糖肽。人血型糖蛋白A(M)和A(N)(GPs - A(M)和A(N))用产气荚膜梭菌神经氨酸酶处理以去除与碳水化合物链相连的所有唾液酸残基,用新城疫病毒(NDV)处理以去除α2 - 3连接的唾液酸残基,并通过埃德曼降解法消除GP - As的N端氨基酸。部分或完全去唾液酸化反应导致GP - A(M)和GP - A(N)与相应抗血清的反应性消失,并出现与VUA和VGA的反应性。消除GP - As的N端氨基酸也导致出现与VUA的反应性。这些结果表明,可以从GP - As制备具有与Vgu糖蛋白相似血清学性质的唾液酸糖蛋白,并表明Vgu糖蛋白的表位结构可能与MN血型表位结构及其在GP - As N端部分的唾液酸残基有关。